Skip to main content

AbCellera Biologics, Inc. (ABCL)

NASDAQ: ABCL · IEX Real-Time Price · USD
20.70
-0.45 (-2.13%)
After-hours:Sep 24, 2021 7:59 PM EDT
21.15
0.00 (0.00%)
At close: Sep 24, 4:00 PM
Market Cap5.89B
Revenue (ttm)447.65M
Net Income (ttm)n/a
Shares Out278.70M
EPS (ttm)0.74
PE Ratio28.58
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,663,151
Open21.00
Previous Close21.15
Day's Range20.76 - 21.31
52-Week Range14.51 - 71.91
Betan/a
Analystsn/a
Price Target45.40 (+114.7%)
Est. Earnings DateNov 11, 2021

About ABCL

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. As of December 31, 2020, the company had 103 discovery programs that are either completed, in progress, or under contract. It has a discovery partnership agreement with Eli Lilly and Company. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.

IndustryBiotechnology
IPO DateDec 11, 2020
Employees302
Stock ExchangeNASDAQ
Ticker SymbolABCL
Full Company Profile

Financial Performance

Financial Statements

News

AbCellera (ABCL), Everest to Co-Develop New Antibody Therapies

AbCellera (ABCL) partners with China-based Everest Medicines to expand the latter???s pipeline across multiple indications.

2 days ago - Zacks Investment Research

AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies

VANCOUVER, British Columbia and SHANGHAI, Sept. 22, 2021 /PRNewswire/ -- AbCellera (Nasdaq: ABCL) and Everest Medicines Limited (HKEX 1952.HK, "Everest") announced today that they have entered into a mu...

3 days ago - PRNewsWire

Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab...

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #AbCellera--Lilly to Supply the EU and EEA with up to 220,000 Doses of Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19

4 days ago - Business Wire

AbCellera Stock Is Moving Higher After Expanded Use Nod For Lilly-Partnered COVID-19 Antibody

The FDA has expanded the Emergency Use Authorization (EUA) for bamlanivimab 700 mg and etesevimab 1400 mg administered together to include post-exposure prophylaxis in certain individuals to prevent SAR...

Other symbols:LLY
1 week ago - Benzinga

Emergency Use Authorization of AbCellera-Discovered Bamlanivimab Administered with Etesevimab Expanded by the FDA to ...

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #AbCellera--EUA of Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19

1 week ago - Business Wire

Why AbCellera Biologics Stock Jumped 7% on Wednesday

The company's drug-development technology is starting to attract attention.

1 week ago - The Motley Fool

AbCellera Shares Are Moving Higher On Licensing Pact With Moderna

AbCellera Biologics Inc (NASDAQ: ABCL) has entered into a research collaboration and license agreement with Moderna Inc (NASDAQ: MRNA) for antibodies for mRNA medicines. The collaboration will leverage ...

Other symbols:MRNA
1 week ago - Benzinga

AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines

1 week ago - Business Wire

AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value Targets

VANCOUVER, British Columbia & BOSTON--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value Targets

1 week ago - Business Wire

AbCellera to Present Virtually at the BofA Securities – Tech Solutions for Drug Discovery Conference

VANCOUVER--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera to Present Virtually at the BofA Securities – Tech Solutions for Drug Discovery Conference

2 weeks ago - Business Wire

Here's Why AbCellera Biologics Stock Gained 10.6% Last Month

Even with its recent gains, the biotech stock is down roughly 53.4% in 2021's trading.

3 weeks ago - The Motley Fool

Why AbCellera Biologics Stock Was Up More Than 17% on Friday

The biopharma company's second quarter was better than expected. The future looks pretty bright, too.

1 month ago - The Motley Fool

AbCellera Reports Q2 2021 Business Results

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Reports Q2 2021 Business Results

1 month ago - Business Wire

Is It Time to Buy 5 of the Nasdaq's Worst-Performing Stocks of 2021?

One particular group of stocks is overrepresented among the exchange's biggest losers this year. That's an important detail.

Other symbols:ACADFOLDSRPTTGTX
1 month ago - The Motley Fool

EQRx and AbCellera Announce Collaboration to Accelerate the Advancement of New Innovative Medicines

CAMBRIDGE, Mass. & VANCOUVER, British Columbia--(BUSINESS WIRE)--EQRx, a company committed to developing and delivering important new medicines at radically lower prices, and AbCellera (Nasdaq: ABCL), a...

1 month ago - Business Wire

Tachyon and AbCellera Collaborate to Develop Novel Antibody Therapeutic Targeting TGF-β Superfamily Member for the Tr...

HOUSTON & VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--Tachyon and AbCellera Collaborate to Develop Novel Antibody Therapeutic Targeting TGF-β Superfamily Member for the Treatment...

1 month ago - Business Wire

AbCellera to Report Second Quarter 2021 Financial Results on August 12, 2021

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera (Nasdaq: ABCL) will announce its second quarter 2021 financial results on Thursday, August 12, 2021 and hold an earnings con...

2 months ago - Business Wire

AbCellera Appoints Neil Berkley as Chief Business Officer

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Appoints Neil Berkley as Chief Business Officer

2 months ago - Business Wire

AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing ...

VANCOUVER, British Columbia--(BUSINESS WIRE)-- #antibodies--AbCellera Continues Expansion & Strengthens Future Pandemic Preparedness with GMP Manufacturing Facility for Therapeutic Antibodies in Canada

3 months ago - Business Wire

AbCellera Announces Secondary Private Sale of 11.9 Million Common Shares

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that certain entities owned and/or controlled, directly or indirectly, by Carl Hansen, Ph.D., Cofounder, Chief Exec...

3 months ago - Business Wire

CORRECTING and REPLACING AbCellera Reports Q1 2021 Business Results

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Reports Q1 2021 Business Results

4 months ago - Business Wire

Why AbCellera Stock Crumbled Despite In-Line Royalties For Covid Drug

AbCellera stock tumbled Friday, despite in-line royalties for its Lilly-partnered Covid drug. Here's why the stock toppled.

4 months ago - Investors Business Daily

AbCellera Reports Q1 2021 Business Results

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Reports Q1 2021 Business Results

4 months ago - Business Wire

AbCellera to Present Virtually at Berenberg Conference on May 18, 2021

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera to Present Virtually at Berenberg Conference on May 18, 2021

4 months ago - Business Wire

AbCellera Partners with Angios to Develop Therapeutics to Combat Blindness Caused by Diabetic Retinopathy

VANCOUVER, British Columbia & INNSBRUCK, Austria--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Partners with Angios to Develop Therapeutics to Combat Blindness Caused by Diabetic Retinopathy

4 months ago - Business Wire